Make an enquiry
Refer a patient
Pay my bill
0808 304 2332

We noticed you are on our UK page. Want to switch regions? Choose from the options:

AU
ES
GenesisCare - logo
Patients
Find a centre
Find a doctor
0808 304 2332
Make an enquiry
Refer a patient
Pay my bill

We noticed you are on our UK page. Want to switch regions? Choose from the options:

AU
ES
Find a centre
Find a doctor
0808 304 2332
2025-08-01T00:00:00.000+01:00

DS8201-772 Destiny

DS8201-772 Destiny
Ovarian cancer

Trial overview

Disease

Ovarian cancer

Sponsor

Daiichi Sankyo

Description

DS8201-772 Destiny Ovarian-01 A Phase 3, Open-label, Multicenter, Randomized Study of Trastuzumab ENGOT Ov89 Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy as First- line Maintenance Therapy in HER2-Expressing Ovarian Cancer

Study details

For detailed information on this trial, please click here

Trial status

Opening October 2025

Location

Oxford

Oxford :::

Principal Investigator

Dr. Rene Roux